Brief: Olix Pharmaceuticals - Olx501a Shows 29.2% Visceral Fat Reduction Versus 10.0% With Comparator In Obese Non-Human Primates
30/07/2026 14:19
BRIEF-Olix Pharmaceuticals - Olx501a Shows 29.2% Visceral Fat Reduction Versus 10.0% With Comparator In Obese Non-Human Primates July 30 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ:
OLIX PHARMACEUTICALS - OLX501A SHOWS 29.2% VISCERAL FAT REDUCTION VERSUS 10.0% WITH COMPARATOR IN OBESE NON-HUMAN PRIMATES
OLIX PHARMACEUTICALS - PLANS CLINICAL TRIAL APPLICATION FOR OLX501A IN FIRST HALF OF 2027
Source text: ID:nBw2dCNyda
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals - Olx501a Shows 29.2% Visceral Fat Reduction Versus 10.0% With Comparator In Obese Non-Human Primates
Brief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug